Chick Embryo Chorioallantoic Membrane as a Platform for Assessing the In Vivo Efficacy of Chimeric Antigen Receptor T-cell Therapy in Solid Tumors
ImmunoHorizons · 2024
DOI: 10.4049/immunohorizons.2400059 ↗Kurz gefasst
Fachartikel in der Zeitschrift ImmunoHorizons, 2024. Verfasst von Allison J Nipper und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Head and Neck Surgery, University of Texas M.D. Anderson Cancer Center, Houston, TX. Hauptthemen laut MEDLINE: Chorioallantoic Membrane, Receptors, Chimeric Antigen, Erb-b2 Receptor Tyrosine Kinases, Immunotherapy, Adoptive. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
The fertilized chicken egg chorioallantoic membrane (CAM), a highly vascularized membrane nourishing the developing embryo, also supports rapid growth of three-dimensional vascularized tumors from engrafted cells and tumor explants. Because murine xenograft models suffer limitations of time, cost, and scalability, we propose CAM tumors as a rapid, efficient screening tool for assessing anti-tumor efficacy of chimeric Ag receptor (CAR) T cells against solid tumors. We tested the efficacy of human epidermal growth factor receptor 2 (HER2)–specific CAR T cells against luminescent, HER2-expressing (FaDu, SCC-47) or HER2-negative (MDA-MB-468) CAM-engrafted tumors. Three days after tumor engraftment, HER2-specific CAR T cells were applied to tumors grown on the CAM. Four days post–CAR T cell treatment, HER2-expressing FaDu and SCC-47 tumors treated with CAR T showed reduced viable cancer cells as assessed by luciferase activity. This reduction in viable tumor cells was confirmed by histology, with lower Ki-67 staining observed in CAR T cell–treated tumors relative to T cell–treated controls. Persistence of CAR T in CAM and tumor tissue 4 days post-treatment was confirmed by CD3 staining. Altogether, our findings support further development of the chick CAM as an in vivo system for rapid, scalable screening of CAR T cell efficacy against human solid tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Head and Neck Surgery, University of Texas M.D. Anderson Cancer Center, Houston, TX.
- Department of Otolaryngology-Head and Neck Surgery, Baylor College of Medicine, Houston, TX.
- Department of Family and Community Medicine, Baylor College of Medicine, Houston, TX.
- Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX.
- Advanced Technology Cores, Baylor College of Medicine, Houston, TX.
- Texas Children's Hospital, Houston, TX.
ORCID-Profile: Allison J Nipper, Emilie A K Warren, Caroline E Porter, Gabrielle A Wells, Mariana Villanueva, Masataka Suzuki, Andrew G Sikora
Förderung
- NCI NIH HHS
Zitieren
APA
Nipper, A. J., Warren, E. A. K., Liao, K. S., Liu, H. C., Michikawa, C., Porter, C. E., Wells, G. A., Villanueva, M., Brasil da Costa, F. H., Veeramachaneni, R., Villanueva, H., Suzuki, M., & Sikora, A. G. (2024). Chick Embryo Chorioallantoic Membrane as a Platform for Assessing the In Vivo Efficacy of Chimeric Antigen Receptor T-cell Therapy in Solid Tumors. ImmunoHorizons. https://doi.org/10.4049/immunohorizons.2400059
Vancouver
Nipper AJ, Warren EAK, Liao KS, Liu HC, Michikawa C, Porter CE, et al. Chick Embryo Chorioallantoic Membrane as a Platform for Assessing the In Vivo Efficacy of Chimeric Antigen Receptor T-cell Therapy in Solid Tumors. ImmunoHorizons. 2024. doi:10.4049/immunohorizons.2400059
BibTeX
@article{Nipper2024,
author = {Nipper, Allison J and Warren, Emilie A K and Liao, Kershena S and Liu, Hsuan-Chen and Michikawa, Chieko and Porter, Caroline E and Wells, Gabrielle A and Villanueva, Mariana and Brasil da Costa, Fabio Henrique and Veeramachaneni, Ratna and Villanueva, Hugo and Suzuki, Masataka and Sikora, Andrew G},
title = {Chick Embryo Chorioallantoic Membrane as a Platform for Assessing the In Vivo Efficacy of Chimeric Antigen Receptor T-cell Therapy in Solid Tumors},
journal = {ImmunoHorizons},
year = {2024},
doi = {10.4049/immunohorizons.2400059}
}
EUVIMED